Decoy Therapeutics develops AI-enabled, adaptable antiviral therapeutics designed to target entry mechanisms shared by many viruses
Decoy Therapeutics develops AI-enabled, adaptable antiviral therapeutics designed to target entry mechanisms shared by many viruses. Its IMP3ACT peptide-conjugate platform supports multiple antiviral programs, with candidates designed for rapid synthesis and manufacturing.